SEARCH

SEARCH BY CITATION

References

  • ACS. (2012). Cancer Facts & Figures 2012. American Cancer Society Inc., Atlanta, GA, USA.
  • Alsina, M., Trudel, S., Vallone, M., Molineaux, C., Kunkel, L. & Goy, A. (2007) Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts), 110, A411.
  • Arastu-Kapur, S., Anderl, J.L., Kraus, M., Parlati, F., Shenk, K.D., Lee, S.J., Muchamuel, T., Bennett, M.K., Driessen, C., Ball, A.J. & Kirk, C.J. (2011) Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events. Clinical Cancer Research, 17, 27342743.
  • Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S. & Vesole, D. (1998) Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. British Journal of Haematology, 102, 11151123.
  • Boyette-Davis, J.A., Cata, J.P., Zhang, H., Driver, L.C., Wendelschafer-Crabb, G., Kennedy, W.R. & Dougherty, P.M. (2011) Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients. Journal of Pain, 12, 10171024.
  • Bringhen, S., Larocca, A., Rossi, D., Cavalli, M., Genuardi, M., Ria, R., Gentili, S., Patriarca, F., Nozzoli, C., Levi, A., Guglielmelli, T., Benevolo, G., Callea, V., Rizzo, V., Cangialosi, C., Musto, P., De Rosa, L., Liberati, A.M., Grasso, M., Falcone, A.P., Evangelista, A., Cavo, M., Gaidano, G., Boccadoro, M. & Palumbo, A. (2010) Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood, 116, 47454753.
  • Demo, S.D., Kirk, C.J., Aujay, M.A., Buchholz, T.J., Dajee, M., Ho, M.N., Jiang, J., Laidig, G.J., Lewis, E.R., Parlati, F., Shenk, K.D., Smyth, M.S., Sun, C.M., Vallone, M.K., Woo, T.M., Molineaux, C.J. & Bennett, M.K. (2007) Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Research, 67, 63836391.
  • Dispenzieri, A., Rajkumar, S.V., Gertz, M.A., Fonseca, R., Lacy, M.Q., Bergsagel, P.L., Kyle, R.A., Greipp, P.R., Witzig, T.E., Reeder, C.B., Lust, J.A., Russell, S.J., Hayman, S.R., Roy, V., Kumar, S., Zeldenrust, S.R., Dalton, R.J. & Stewart, A.K. (2007) Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clinic Proceedings, 82, 323341.
  • van de Donk, N.W., Lokhorst, H.M., Dimopoulos, M., Cavo, M., Morgan, G., Einsele, H., Kropff, M., Schey, S., Avet-Loiseau, H., Ludwig, H., Goldschmidt, H., Sonneveld, P., Johnsen, H.E., Blade, J., San-Miguel, J.F. & Palumbo, A. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews, 37, 266283.
  • Durie, B.G., Harousseau, J.L., Miguel, J.S., Blade, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., Ludwig, H., Gahrton, G., Beksac, M., Crowley, J., Belch, A., Boccadaro, M., Cavo, M., Turesson, I., Joshua, D., Vesole, D., Kyle, R., Alexanian, R., Tricot, G., Attal, M., Merlini, G., Powles, R., Richardson, P., Shimizu, K., Tosi, P., Morgan, G. & Rajkumar, S.V. (2006) International uniform response criteria for multiple myeloma. Leukemia, 20, 14671473.
  • Greipp, P.R., San Miguel, J., Durie, B.G., Crowley, J.J., Barlogie, B., Blade, J., Boccadoro, M., Child, J.A., Avet-Loiseau, H., Kyle, R.A., Lahuerta, J.J., Ludwig, H., Morgan, G., Powles, R., Shimizu, K., Shustik, C., Sonneveld, P., Tosi, P., Turesson, I. & Westin, J. (2005) International staging system for multiple myeloma. Journal of Clinical Oncology, 23, 34123420.
  • Hideshima, T., Richardson, P., Chauhan, D., Palombella, V.J., Elliott, P.J., Adams, J. & Anderson, K.C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Research, 61, 30713076.
  • Huang, H.Q., Brady, M.F., Cella, D. & Fleming, G. (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. International Journal of Gynecological Cancer, 17, 387393.
  • Kanayama, H., Tanaka, K., Aki, M., Kagawa, S., Miyaji, H., Satoh, M., Okada, F., Sato, S., Shimbara, N. & Ichihara, A. (1991) Changes in expressions of proteasome and ubiquitin genes in human renal cancer cells. Cancer Research, 51, 66776685.
  • Kane, R.C., Bross, P.F., Farrell, A.T. & Pazdur, R. (2003) Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. The Oncologist, 8, 508513.
  • Kirk, C.J., Jiang, J., Muchamuel, T., Dajee, M., Swinarski, D., Aujay, M., Bennett, M.K., Yang, J., Lewis, E., Laidig, G. & Molineaux, C.J. (2008) The Selective Proteasome Inhibitor Carfilzomib Is Well Tolerated in Experimental Animals with Dose Intensive Administration. Blood (ASH Annual Meeting Abstracts), 112, A2765.
  • Kuhn, D.J., Chen, Q., Voorhees, P.M., Strader, J.S., Shenk, K.D., Sun, C.M., Demo, S.D., Bennett, M.K., van Leeuwen, F.W., Chanan-Khan, A.A. & Orlowski, R.Z. (2007) Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood, 110, 32813290.
  • Kyle, R.A. & Rajkumar, S.V. (2008) Multiple myeloma. Blood, 111, 29622972.
  • Laubach, J.P., Richardson, P.G. & Anderson, K.C. (2010) The evolution and impact of therapy in multiple myeloma. Medical Oncology, 27(Suppl 1), S1S6.
  • Martin, T., Singhal, S.B., Vij, R.M.W., Stewart, A.K., Jagganath, S., Lonial, S., Jakubowiak, A.J., Kukreti, V., Bahlis, N.J., Alsina, M., Chanan-Khan, A.A., Somlo, G., Buadi, F., Reu, F.J., Zonder, J.A., Song, K., Stadtmauer, E.A., Wong, A.F., Vallone, M., Chang, Y.-L., Kauffman, M., Orlowski, R.Z. & Siegel, D.S.D. (2010) Baseline peripheral neuropathy does not impact the efficacy and tolerability of the novel proteasome inhibitor carfilzomib (CFZ): results of a subset analysis of a phase 2 trial In patients with relapsed and refractory multiple myeloma (R/R MM). Blood (ASH Annual Meeting Abstracts), 116, A3031.
  • Mohty, B., El-Cheikh, J., Yakoub-Agha, I., Moreau, P., Harousseau, J.L. & Mohty, M. (2010) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica, 95, 311319.
  • Mohty, B., El-Cheikh, J., Yakoub-Agha, I., Avet-Loiseau, H., Moreau, P. & Mohty, M. (2012) Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents. Leukemia, 26, 7385.
  • Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., Rekhtman, G., Masliak, Z., Robak, T., Shubina, A., Arnulf, B., Kropff, M., Cavet, J., Esseltine, D.L., Feng, H., Girgis, S., van de Velde, H., Deraedt, W. & Harousseau, J.L. (2011) Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. The Lancet Oncology, 12, 431440.
  • Niesvizky, R., Richardson, P.G., Rajkumar, S.V., Coleman, M., Rosinol, L., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Boral, A.L., Esseltine, D.L., Anderson, K.C. & Blade, J. (2008) The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma. British Journal of Haematology, 143, 4653.
  • O'Connor, O.A., Stewart, A.K., Vallone, M., Molineaux, C.J., Kunkel, L.A., Gerecitano, J.F. & Orlowski, R.Z. (2009) A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clinical Cancer Research, 15, 70857091.
  • Papadopoulos, K., Lee, P., Singhal, S., Holahan, J., Tolcher, A., Patnaik, A., Vesole, D., Rosen, S., Rosen, P., Bilotti, E., Woo, T., Lee, S., Hannah, A. & Siegel, D. (2011) PX-171-007: a phase 1b study evaluating the safety and efficacy of a 30-minute IV infusion of carfilzomib in patients with relapsed and/or refractory (R/R) multiple myeloma (MM) (Abstract 0898). Haematologica (Abstracts from the 16th Annual Congress of the EHA), 96, 374.
  • Parlati, F., Lee, S.J., Aujay, M., Suzuki, E., Levitsky, K., Lorens, J.B., Micklem, D.R., Ruurs, P., Sylvain, C., Lu, Y., Shenk, K.D. & Bennett, M.K. (2009) Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood, 114, 34393447.
  • Plosker, G.L. (2008) Pegylated liposomal Doxorubicin: a review of its use in the treatment of relapsed or refractory multiple myeloma. Drugs, 68, 25352551.
  • Rajkumar, S.V. (2009) Multiple myeloma. Current Problems in Cancer, 33, 764.
  • Richardson, P.G., Sonneveld, P., Schuster, M.W., Irwin, D., Stadtmauer, E.A., Facon, T., Harousseau, J.L., Ben-Yehuda, D., Lonial, S., Goldschmidt, H., Reece, D., San-Miguel, J.F., Blade, J., Boccadoro, M., Cavenagh, J., Dalton, W.S., Boral, A.L., Esseltine, D.L., Porter, J.B., Schenkein, D. & Anderson, K.C. (2005) Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New England Journal of Medicine, 352, 24872498.
  • Siegel, D., Martin, T., Wang, M., Vij, R., Jakubowiak, A.J., Jagannath, S., Lonial, S., Kukreti, V., Bahlis, N.J., Alsina, M., Chanan-Khan, A.A., Somlo, G., Buadi, F., Reu, F.J., Zonder, J.A., Song, K., Stadtmauer, E., Wong, A.F., Vallone, M., Chang, Y.-L., Kauffman, M., Orlowski, R.Z., Stewart, A.K. & Singhal, S.B. (2010) The multiple myeloma research consortium results of PX-171-003-A1, an open-label, single-arm, phase 2 (ph 2) study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 116, A985.
  • Siegel, R., Ward, E., Brawley, O. & Jemal, A. (2011a) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA: A Cancer Journal for Clinicians, 61, 212236.
  • Siegel, S., Kaufman, J., Wang, M., Martin, T., Jagannath, S., Niesvizky, R., Reu, F., Alsina, M., Badros, A., Gabrail, N., Kukreti, V., Singhal, S., Le, M., Kotlovker, D., Bomba, D., Hannah, A. & Vij, R. (2011b) A summary of safety and efficacy data achieved with long-term carfilzomib (CFZ) treatment in patients with relapsed and/or refractory multiple myeloma (R/R MM) Haematologica, 96, 126, Abstract 0302.
  • Siegel, D., Martin, T., Wang, M., Vij, R., Lonial, S., Kukreti, V., Bahlis, N., Alsina, M., Somlo, G., Buadi, F., Reu, F., Song, K., Kunkel, L.A., Wong, A.F., Vallone, M., Orlowski, R., Stewart, A.K., Singhal, S., Jagannath, S. & Jakubowiak, A. (2011c) PX-171-003-A1, an open-label, single-arm phase (Ph) 2 study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (R/R MM): long-term follow-up and subgroup analysis. Journal of Clinical Oncology (Meeting Abstracts), 29, Abstract 8027.
  • Singhal, S., Siegel, D.S., Martin, T., Vij, R., Wang, L., Jakubowiak, A.J., Lonial, S., Kukreti, V., Zonder, J.A., Wong, A.F., McCulloch, L., Badros, A.Z., Niesvizky, R., Orlowski, R.Z., Stewart, A.K., Kotlovker, D. & Jagannath, S. (2011) Integrated safety from phase 2 studies of monotherapy carfilzomib in patients with relapsed and refractory multiple myeloma (MM): an updated analysis. Blood (ASH Annual Meeting Abstracts), 118, Abstract 1876.
  • Vij, R., Kaufman, J.L., Jakubowiak, A.J., Stewart, A.K., Jagannath, S., Kukreti, V., McDonagh, K.T., Alsina, M., Bahlis, N.J., Belch, A., Reu, F.J., Gabrail, N.Y., Matous, J., Vesole, D.H., Orlowski, R.Z., Le, M.H., Lee, P., Wang, M. & the Multiple Myeloma Research Consortium. (2010) Carfilzomib: high single agent response rate with minimal neuropathy even in high-risk patients (Abstract). Blood (ASH Annual Meeting Abstracts), 116; Abstract 1938.
  • Vij, R., Wang, M., Kaufman, J., Lonial, S., Jakubowiak, A., Stewart, A., Kukreti, V., Jagannath, S., McDonagh, K., Alsina, M., Bahlis, N., Reu, F., Gabrail, N., Belch, A., Matous, J., Lee, P., Rosen, P., Sebag, M., Vesole, D., Kunkel, L., Wear, S., Wong, A., Orlowski, R. & Siegel, D.S. (2012)An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naïve patients with relapsed and/or refractory multiple myeloma. Blood, 119, 56615670.